

Peter StÄörkel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8588141/publications.pdf>

Version: 2024-02-01

89
papers

6,272
citations

101384

36
h-index

71532

76
g-index

91
all docs

91
docs citations

91
times ranked

6935
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. <i>Gut</i> , 2022, 71, 1856-1866.	6.1	17
2	Liver Decompensation after Bariatric Surgery in the Absence of Cirrhosis. <i>Obesity Surgery</i> , 2022, 32, 1227-1235.	1.1	4
3	The fecal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 788-799.	1.8	66
4	Intestinal virome in patients with alcohol use disorder and after abstinence. <i>Hepatology Communications</i> , 2022, 6, 2058-2069.	2.0	18
5	Restoring an adequate dietary fiber intake by inulin supplementation: a pilot study showing an impact on gut microbiota and sociability in alcohol use disorder patients. <i>Gut Microbes</i> , 2022, 14, 2007042.	4.3	15
6	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022, 12, 433.	1.3	6
7	Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study. <i>EBioMedicine</i> , 2022, 80, 104033.	2.7	7
8	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021, 56, 1-11.	2.3	22
9	Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101661.	0.7	6
10	Dietary fiber deficiency as a component of malnutrition associated with psychological alterations in alcohol use disorder. <i>Clinical Nutrition</i> , 2021, 40, 2673-2682.	2.3	11
11	Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101721.	0.7	5
12	Que serait un dispositif hospitalier adéquat au soutien de la transition chez les patients alcooliques?. <i>Cahiers De Psychologie Clinique</i> , 2021, n° 57, 169-192.	0.1	0
13	Critical Role of LSEC in Post-Hepatectomy Liver Regeneration and Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8053.	1.8	20
14	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2021, 12, 699253.	1.3	45
15	Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms. <i>Translational Psychiatry</i> , 2021, 11, 503.	2.4	32
16	Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease. <i>Metabolites</i> , 2021, 11, 766.	1.3	3
17	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12687.	1.8	10
18	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	3.6	151

#	ARTICLE	IF	CITATIONS
19	The <i>Candida albicans</i> exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020, 72, 391-400.	1.8	119
20	1,8-Cineole promotes G0/G1 cell cycle arrest and oxidative stress-induced senescence in HepG2 cells and sensitizes cells to anti-senescence drugs. <i>Life Sciences</i> , 2020, 243, 117271.	2.0	47
21	Gut Microbiota-Induced Changes in $\hat{1}^2$ -Hydroxybutyrate Metabolism Are Linked to Altered Sociability and Depression in Alcohol Use Disorder. <i>Cell Reports</i> , 2020, 33, 108238.	2.9	87
22	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co \hat{E} Metabolism in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020, 4, 1168-1182.	2.0	22
23	Virulence-related genes in fecal metagenomes associated with mortality in patients with alcoholic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, S1-S2.	1.8	0
24	Defective gut adaptive immunity during early alcoholic liver disease. <i>Journal of Hepatology</i> , 2020, 73, S185-S186.	1.8	0
25	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020, 11, 370.	1.3	11
26	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 159, 1839-1852.	0.6	103
27	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. <i>Gut Microbes</i> , 2020, 12, 1782157.	4.3	83
28	Deficiency of Intestinal $\hat{1}^2$ -Fucosylation Exacerbates Ethanol \hat{E} Induced Liver Disease in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1842-1851.	1.4	11
29	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
30	Defective HNF4 α -dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019, 10, 3126.	5.8	124
31	SAT-071-Insulin resistance in cirrhotic patients: results from a large prospective study. <i>Journal of Hepatology</i> , 2019, 70, e658-e659.	1.8	0
32	Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital. <i>BMC Infectious Diseases</i> , 2019, 19, 738.	1.3	6
33	246 \hat{E} Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019, 156, S-1186.	0.6	2
34	Deficient IL $\hat{6}$ /Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. <i>Hepatology Communications</i> , 2019, 3, 867-882.	2.0	24
35	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1878-1892.	1.1	35
36	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G585-G597.	1.6	23

#	ARTICLE	IF	CITATIONS
37	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	13.7	493
38	Fibroscan Reliably Rules Out Advanced Liver Fibrosis and Significant Portal Hypertension in Alcoholic Patients. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 772-778.	1.1	15
39	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. <i>Hepatology</i> , 2019, 69, 2180-2195.	3.6	52
40	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019, 68, 1504-1515.	6.1	202
41	The gut microbiota: A new target in the management of alcohol dependence?. <i>Alcohol</i> , 2019, 74, 105-111.	0.8	36
42	Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways. <i>Life Sciences</i> , 2018, 199, 48-59.	2.0	66
43	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	1.8	144
44	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 α Transactivation in Steatohepatitis. <i>Cell Metabolism</i> , 2018, 27, 339-350.e3.	7.2	62
45	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. <i>Clinical Science</i> , 2018, 132, 199-212.	1.8	78
46	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. <i>Hepatology</i> , 2018, 67, 2150-2166.	3.6	189
47	Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. <i>Oncotargets and Therapy</i> , 2018, Volume 11, 7143-7153.	1.0	6
48	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 614-625.	3.7	91
49	Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. <i>Cancer Science</i> , 2018, 109, 2141-2152.	1.7	21
50	A role for the peripheral immune system in the development of alcohol use disorders?. <i>Neuropharmacology</i> , 2017, 122, 148-160.	2.0	66
51	Treatment of severe alcoholic hepatitis: past, present and future. <i>European Journal of Clinical Investigation</i> , 2017, 47, 531-539.	1.7	25
52	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. <i>Hepatology</i> , 2017, 65, 475-490.	3.6	91
53	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2829-2841.	3.9	336
54	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. <i>PLoS ONE</i> , 2017, 12, e0170933.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2016, 36, 331-339.	1.8	84
56	To chew or not to chew: that's the question. <i>Acta Clinica Belgica</i> , 2016, 71, 187-189.	0.5	6
57	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. <i>Cell Host and Microbe</i> , 2016, 19, 227-239.	5.1	284
58	Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. <i>Gastroenterology</i> , 2016, 150, 903-910.e8.	0.6	131
59	Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 53-66.	0.7	130
60	A dysbiotic subpopulation of alcohol-dependent subjects. <i>Gut Microbes</i> , 2015, 6, 388-391.	4.3	49
61	New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?. <i>Journal of Hepatology</i> , 2015, 63, 765-766.	1.8	5
62	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 2015, 45, 609-623.	1.7	193
63	Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats. <i>Nutrition and Cancer</i> , 2015, 67, 748-760.	0.9	5
64	Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. <i>Gastroenterology</i> , 2015, 148, 203-214.e16.	0.6	266
65	Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. <i>Hepatology</i> , 2015, 61, 883-894.	3.6	245
66	Ras in digestive oncology. <i>Current Opinion in Oncology</i> , 2014, 26, 454-461.	1.1	11
67	Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4485-93.	3.3	652
68	Role of Inflammatory Pathways, Blood Mononuclear Cells, and Gut-Derived Bacterial Products in Alcohol Dependence. <i>Biological Psychiatry</i> , 2014, 76, 725-733.	0.7	163
69	Impact of PPAR- δ induction on glucose homeostasis in alcohol-fed mice. <i>Clinical Science</i> , 2013, 125, 501-511.	1.8	12
70	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. <i>Hepatology</i> , 2013, 58, 108-119.	3.6	187
71	Participation of liver progenitor cells in liver regeneration: lack of evidence in the AAF/PH rat model. <i>Laboratory Investigation</i> , 2012, 92, 72-81.	1.7	15
72	Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: A rationale for combination with radiation therapy. <i>Radiotherapy and Oncology</i> , 2012, 105, 64-71.	0.3	17

#	ARTICLE	IF	CITATIONS
73	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
74	Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain, Behavior, and Immunity, 2012, 26, 911-918.	2.0	237
75	Antiviral therapy and fibrosis progression in patients with mild to moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and Liver Disease, 2012, 44, 603-609.	0.4	12
76	The Loss of Metabolic Control on Alcohol Drinking in Heavy Drinking Alcohol-Dependent Subjects. PLoS ONE, 2012, 7, e38682.	1.1	58
77	Ras inhibition in hepatocarcinoma by <i>S-trans-trans-farnesylthiosalicylic acid</i> : Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Molecular Carcinogenesis, 2012, 51, 816-825.	1.3	7
78	NF- κ B, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. European Journal of Clinical Investigation, 2010, 40, 575-584.	1.7	28
79	Research update for articles published in EJCI in 2008. European Journal of Clinical Investigation, 2010, 40, 770-789.	1.7	1
80	Genetic factors predicting response to interferon treatment for viral hepatitis C. Gut, 2007, 57, 440-442.	6.1	5
81	Role of signal transducer and activator of transcription 3 in liver fibrosis progression in chronic hepatitis C-infected patients. Laboratory Investigation, 2007, 87, 173-181.	1.7	18
82	Blunted DNA synthesis and delayed S-phase entry following inhibition of Cdk2 activity in the regenerating rat liver. Laboratory Investigation, 2005, 85, 562-571.	1.7	8
83	Response to an experimental HBV vaccine permits withdrawal of HBIG prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transplantation, 2005, 11, 1228-1234.	1.3	58
84	Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. Journal of Hepatology, 2005, 43, 687-695.	1.8	26
85	Expression and DNA-Binding Activity of Signal Transducer and Activator of Transcription 3 in Alcoholic Cirrhosis Compared to Normal Liver and Primary Biliary Cirrhosis in Humans. American Journal of Pathology, 2003, 162, 587-596.	1.9	20
86	Oxidative stress, KLF6 and transforming growth factor- β 2 up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. Journal of Hepatology, 2003, 39, 538-546.	1.8	129
87	Limited lamivudine and long-term hepatitis B immunoglobulin immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation. Transplantation, 2002, 74, 408-410.	0.5	4
88	Causal role of the gut microbiota in the development of behavioral alterations associated with alcohol dependence. Frontiers in Neuroscience, 0, 12, .	1.4	0
89	The Gut Microbiota Drives Metabolic Disorders Which Compromise Sociability in Alcoholic Patients. SSRN Electronic Journal, 0, , .	0.4	0